JPRN-UMIN000006591招募中2 期
Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer. -Phase II study- - XP+HER for previously untreated HER2 positive advanced gastric cancer. -Phase II study
SGCSG: Shimane Gastroenterological Cancer Study Group0 个研究点目标入组 25 人开始时间: 2011年10月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Forbidden case to use capecitabine, Cisplatin and Trastuzumab. (2) R1 operation(histlogically positive PM, OM, LM, VM). (3) Infection or inflammatory case. (4) Severe heart disease. (5) Severe complicated case such as ileus, interstitial pneumonia, uncontrolled DM, liver cirrhosis etc. (6) Severe ascites and/or pleural effusion. (7) Multiple bone metastasis. (8) Clinical suspicion or previous history of metastasis to brain or meninges. (9) Difficulty to join the trial due to psychosis or psychotic symptoms or central nervous system damage. (10)Complicated other active cancer. (11)patient who want to be pregnant and /or pregnant woman. (12)Intend to make pregnant. (13)Active hepatitis type HBs positive. (14)Otherwise determined by investigators or site principal investigators to be unsuitable for participation in study.
研究者
相似试验
已完成
2 期
Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer.-Phase II studyuntreated HER2 positive advanced gastric cancerJPRN-UMIN000006590Herceptin Database of Shimane Prefecture25
尚未招募
不适用
First-line trastuzumab, gemcitabine, cisplatin and nivolumab in advanced HER2-positive biliary tract cancer: a multicenter, openlabel, single-arm phase Ib/II trial (HERBOT)KCT0008250Yonsei University Health System, Severance Hospital44
尚未招募
不适用
eoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 studyBreast cancerNL-OMON53609Antoni van Leeuwenhoek Ziekenhuis30
进行中（未招募）
不适用
CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION. - CHERLOBMALIGNANT NEOPLASM FEMALE BREASTMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2006-001839-21-ITGLAXO SMITH KLINE120
进行中（未招募）
不适用
Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M. - NDEUCTR2007-003156-11-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE